Low impact

FDA approved Moderna's updated 2026-2027 COVID-19 vaccines, including mRNA-1345 (Mnexspike) for a new formula and Spikevax for the 2026-2027 formula.

Moderna announced FDA approval for its updated 2026-2027 COVID-19 vaccines, including MNexspike with a new formula and Spikevax for the 2026-2027 formula.

Related assets

MRNA

Coming up for MRNA

Explore next

Latest MRNA news

Jin1010/23, 05:33 AM
Spot gold briefly fell below $4,050 and spot silver dropped over 6% intraday, while the Nasdaq fell 2.6% on AI-spending concerns, Meta's spending commitments rose to $825 billion with its 5-year CDS near 120bp, US 10-year Treasury yield fell below 5%, French 10-year yield exceeded US yields for the first time in 13 years, Turkey's central bank cut rates 100bp to 36%, and US initial jobless claims fell to 194,000.
Jin1010/23, 03:02 AM
US stocks closed lower Thursday: Nasdaq fell 2.6%, S&P 500 fell 1.2%, Dow edged up, with tech stocks hit hard including SpaceX down 9%, Meta down nearly 7%, Nvidia down 4.4%, SK Hynix down 8%, and Moderna down 17%; Nasdaq Golden Dragon China Index fell 1.19%, Alibaba down over 2%, NetEase down over 3%.
Jin1010/23, 12:41 AM
Moderna shares fell nearly 25% intraday and Merck fell 3.7% after trial data on their jointly developed cancer vaccine, combined with Merck's Keytruda, was briefly and prematurely posted on a medical website before being removed ahead of a scheduled ESMO presentation.